Literature DB >> 8376810

T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects.

C S Via1, G C Tsokos, B Bermas, M Clerici, G M Shearer.   

Abstract

To assess interactions between T cells and APC in patients with SLE, PBL were stimulated in vitro and IL-2 production measured after stimulation with either a MHC-self-restricted Ag (influenza A virus) or an Ag which can use both MHC-self-restricted or unrestricted T cell activation pathways (HLA-alloantigen). SLE patients (n = 26) and controls (n = 8) were categorized as responder (+) or nonresponder (-) for each stimulus and grouped according to their paired response pattern. All controls responded to both influenza virus (Flu) or alloantigen (Allo) and were categorized as +/+. In contrast, SLE patient response patterns were heterogeneous with no evidence for a single SLE-associated defect. Instead, SLE patient responses fell into one of three different patterns: a) normal responses to both Flu and Allo (+/+), observed in nine (35%) patients; b) defective responses to Flu but intact Allo responses (-/+) observed in 12 (46%) SLE patients; and c) defective responses to both Flu and Allo (-/-), observed in five (19%) SLE patients. There was no statistically significant correlation between immune response pattern and the use of immunosuppressants. Further analysis of -/- SLE patients indicated defects in APC function and in both CD4+ and CD8+ T cell function. In contrast, cell depletion and add-back studies in -/+ SLE patients demonstrated defects in APC function only. Thus, similar to the well recognized clinical heterogeneity among SLE patients, our data support the concept that SLE patients are heterogeneous with respect to in vitro T cell-APC function, exhibiting responses ranging from normal function to defects in APC and in both T cell subsets. Prospective studies are in progress to determine the clinical relevance of these observations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376810

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Chronic administration of dexamethasone results in Fc receptor up-regulation and inhibition of class I antigen expression on macrophages from MRL/lpr autoimmune mice.

Authors:  S H Zuckerman; G F Evans; N Bryan
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 2.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

3.  T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.

Authors:  Matthew J Loza; A Shane Anderson; Kenneth S O'Rourke; James Wood; Islam U Khan
Journal:  Cell Immunol       Date:  2011-07-18       Impact factor: 4.868

Review 4.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 5.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

7.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

9.  Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregulatory Th1 Response.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Mark Haas; Clifton L Dalgard; Brian C Schaefer; Charles S Via
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

10.  The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation.

Authors:  R A Puliaev; I A Puliaeva; A E Ryan; C S Via
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2005-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.